产品
编 号：F245957
分子式：C19H17N2NaO4S
分子量：392.4
分子式：C19H17N2NaO4S
分子量：392.4
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
25mg
480
In-stock
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 198470-85-8
产品详情
生物活性：
Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
体内研究：
Parecoxib Sodium (intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10?mg/kg shows higher levels of percentage of time spent in the open arms.Animal Model:Naive adult male ICR mice, 15?weeks old and weighing 25-35?g
Dosage:2.5?mg/kg, 5.0 ?mg/kg or 10?mg/kg
Administration:Intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days
Result:Exerted an anxiolytic-like effect in the elevated plus-maze test.
体外研究：
Parecoxib Sodium (0-200?μM; 24-48 hours) inhibits the cell proliferation of GBM cells in a dose-dependent manner in GBM cells.Parecoxib Sodium (200?μM; 24-48 hours) results in a decreased migratory ability of U343 cells than PBS-treated group.
Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
体内研究：
Parecoxib Sodium (intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10?mg/kg shows higher levels of percentage of time spent in the open arms.Animal Model:Naive adult male ICR mice, 15?weeks old and weighing 25-35?g
Dosage:2.5?mg/kg, 5.0 ?mg/kg or 10?mg/kg
Administration:Intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days
Result:Exerted an anxiolytic-like effect in the elevated plus-maze test.
体外研究：
Parecoxib Sodium (0-200?μM; 24-48 hours) inhibits the cell proliferation of GBM cells in a dose-dependent manner in GBM cells.Parecoxib Sodium (200?μM; 24-48 hours) results in a decreased migratory ability of U343 cells than PBS-treated group.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备